Seven Bridge Financial Group, LLC Fate Therapeutics Inc Transaction History

Seven Bridge Financial Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 15, 2022	SELL	$29.67 - $60.28 $134,553 - $273,369	-4,535 Closed	0 $0
Q4 2021 Jan 20, 2022	BUY	$47.84 - $64.34 $216,954 - $291,781	4,535 New	4,535 $265,000
Q4 2021 Jan 20, 2022	SELL	$47.84 - $64.34 $216,954 - $291,781	-4,535 Closed	0 $0
Q3 2021 Oct 14, 2021	SELL	$59.27 - $95.73 $722,797 - $1.17 Million	-12,195 Reduced 72.89%	4,535 $269,000
Q2 2021 Jul 26, 2021	BUY	$67.25 - $92.52 $906,664 - $1.25 Million	13,482 Added 415.09%	16,730 $1.45 Million
Q1 2021 Apr 20, 2021	BUY	$72.16 - $117.4 $8,803 - $14,322	122 Added 3.9%	3,248 $268,000
Q4 2020 Jan 19, 2021	BUY	$38.09 - $100.95 $119,069 - $315,569	3,126 New	3,126 $284,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $157M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Seven Bridge Financial Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Seven Bridge Financial Group, LLC with notifications on news.